In this context, scientific interest in the relationship between these two conditions is increasing as newer antihyperglycemic agents, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor (GLP1R) agonists, have shown some benefit on liver fat content and histologic regression of NASH [39], but also clinically significant benefits on cardiovascular outcomes, including the risk of hospitalization for HF, independent of T2DM status [39, 40]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.